|
| Status |
Public on Mar 26, 2020 |
| Title |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer |
| Organisms |
Homo sapiens; synthetic construct |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
Other
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| Web link |
https://pubmed.ncbi.nlm.nih.gov/32220301/
|
| |
|
| Citation(s) |
32220301 |
| |
| Submission date |
Feb 22, 2019 |
| Last update date |
Jun 25, 2020 |
| Contact name |
Ping Mu |
| E-mail(s) |
[email protected]
|
| Organization name |
UT Southwestern Medical Center
|
| Department |
Human Oncology and Pathogenesis
|
| Lab |
Mu Lab
|
| Street address |
6000 Harry Hines Blvd., NA6.308A
|
| City |
Dallas |
| State/province |
TX |
| ZIP/Postal code |
76092 |
| Country |
USA |
| |
|
| Platforms (3) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
| GPL19604 |
Illumina HiSeq 2500 (synthetic construct) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (453)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE126917 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [RNA-seq] |
| GSE127241 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [ATAC-seq] |
| GSE127957 |
Loss of CHD1 promotes chromatin dysregulation leading to heterogeneous mechanisms of resistance to hormone therapy in prostate cancer [shRNA screen] |
|
| Relations |
| BioProject |
PRJNA523724 |
Less...
More...